Are we progressing in prostate cancer management?

Affiliations

¹ Department of Urology, University of Rochester Medical & Dental School, NY, USA.
² St George's University of London Medical School, London, United Kingdom.

Hiten Rh Patel et al. Asian J Urol. 2021 Apr.

. 2021 Apr;8(2):241-242.

doi: 10.1016/j.ajur.2020.09.001. Epub 2020 Sep 11.

¹ Department of Urology, University of Rochester Medical & Dental School, NY, USA.
² St George's University of London Medical School, London, United Kingdom.

No abstract available

References

1. Bray F., Ferlay J., Soerjomataram I., Siegel R., Torre L., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
1. Lawrence M., Porter L., Clouston D., Murphy D., Frydenberg M., Taylor R. Knowing what's growing: why ductal and intraductal prostate cancer matter. Sci Transl Med. 2020;12:eaaz0152. doi: 10.1126/scitranslmed.aaz0152. - DOI - PubMed
1. Meeks J., Zhao L., Cashy J., Kundu S. Incidence and outcomes of ductal carcinoma of the prostate in the USA: analysis of data from the Surveillance, Epidemiology, and End Results program. BJU Int. 2011;109:831–834. - PubMed
1. Wu Y., Chen S., Wang S., Li X., Cai H., Lin Y. Prognostic values of clinicopathological characteristics and survival outcomes in prostate infiltrating ductal carcinoma: a population-based study. Oncotarget. 2017;8:29048–29055. - PMC - PubMed
1. Liu M., Jin K., Qiu S., Xu P., Zhang M., Cai W. Oncological outcomes of patients with ductal adenocarcinoma of the prostate receiving radical prostatectomy or radiotherapy. Asian J Urol. 2020;8:227–234. - PMC - PubMed